Company: RCUS
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001724521-25-000063
Chunk: 190

Company: Arcus Biosciences, Inc.
Filing Date: 2025-05-06
Form: 10-Q
Item: Part I, Item 1
Chunk 190
---
' EQUITY Current liabilities:Accounts payable$22 $18 Deferred revenue ($72 and $85 to a related party)72 85 Other current liabilities98 123 Total current liabilities192 226  Deferred revenue, noncurrent ($219 and $234 to a related party)219 234 Long-term debt48 48 Other noncurrent liabilities166 157  Commitments Stockholders’ equity:Common stock and additional paid-in capital: $0.0001 par value per share; 400.0 shares authorized; 105.9 shares in 2025 and 92.2 shares in 2024 issued and outstanding1,775 1,617 Accumulated deficit(1,244)(1,132)Total stockholders’ equity531 485 Total liabilities and stockholders’ equity$1,156 $1,150 

See accompanying notes.

3

ARCUS BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

(In millions)

(unaudited)

Number of shares of common stockCommon stock and additional paid-in capitalAccumulated deficit Accumulatedothercomprehensive loss Totalstockholders’ equity Balance at December 31, 202375.5$1,311 $(849)$— $462 Issuance of common stock (see Note 3, Related party - Gilead Sciences, Inc. and Note 13, Stockholders' Equity)15.2228 — — 228 Issuance of common stock in connection with our equity award programs0.22 — — 2 Stock-based compensation—20 — — 20 Other comprehensive loss—— — (1)(1)Net loss—— (4)— (4)Balance at March 31, 202490.9$1,561 $(853)$(1)$707 Balance at December 31, 202492.2$1,617 $(1,132)$— $485 Issuance of common stock (see Note 3, Related party - Gilead Sciences, Inc. and Note 13, Stockholders' Equity)13.6142——142 Issuance of common stock in connection with our equity award programs0.1———— Stock-based compensation—16——16 Net loss——(112)—(112)Balance at March 31, 2025105.9